Results show consistent improvements in wakefulness, cataplexy, and quality of life with oveporexton for patients with narcolepsy.
|Articles|July 16, 2007
Three lots of Merck antibiotic recalled
Merck has announced the recall of three lots of ertapenem sodium (Invanz) for injection after broken glass was found in two vials of reconstituted solution.
Advertisement
Merck has announced the recall of three lots of ertapenem sodium (Invanz) for injection after broken glass was found in two vials of reconstituted solution. The affected lots are 0803930, 0803940, and 0803950 and all carry an expiration date of October 2008. Pharmacists are advised to immediately stop dispensing any product from the lots affected by this recall.
To see more Hot off the Press news articles,
To go to the Drug Topics homepage,
Advertisement
Related to this article
Researchers assess the differences in out-of-pocket spending on brand name compared with generic medication.
Practical takeaways to improve real‑world clinic outcomes for PAINWeek 2026.
Starting with Exelixis’ condition on in-house dispensing data, manufacturers are introducing a new approach to 340B claims focused on transparency.
The trial found that up to 25 days of nirmatrelvir-ritonavir did not improve cognitive, autonomic, or exercise-related symptoms compared with placebo.
Digital innovation and proactive patient care are converging to transform clinical practice while preserving essential safeguards.
James Barnes, CPhT, explains why respecting a patient's time isn't about speed and how he landed in the pharmacy by chance.
ACIP changes, new court rulings, and coverage gaps threaten vaccines, pharmacists’ reimbursement, and children's access through Vaccine For Children.
Advertisement
Advertisement
Trending on Drug Topics
1
Johnson & Johnson Next Major Drugmaker to Require 340B Claims Data
2
Expert Discusses Flu and COVID-19 Vaccine Guidance
3
Nirmatrelvir-Ritonavir Shows No Benefit for Long COVID
4
Oveporexton Met Primary, Key Secondary End Points in Phase 3 Studies
5